Sex-related differences in clinical outcomes and predictive factors in the very elderly patients with ACS undergoing PCI

Jia-li Wang1, Xiao-quan He1, Chun-yan Guo1, Hui Chen1, Hong-wei Li1,2,3 and Shu-mei Zhao*

1Department of Cardiology, Cardiovascular Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China, 2Department of Internal Medical, Medical Health Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China, 3Beijing Key Laboratory of Metabolic Disorder Related Cardiovascular Disease, Beijing, China

Background: As shown in previous studies, there may be sex-related differences in clinical outcomes in patients with acute coronary syndromes (ACS) after percutaneous coronary intervention (PCI). However, the benefits of PCI in very elderly ACS patients and the gender differences were poorly described and understood. We investigated the clinical characteristics and outcomes after PCI by sex stratification, and the predictive factors of major adverse cardiovascular and cerebrovascular events (MACCE) in this very elderly ACS cohort.

Methods: A total of 1,676 consecutive ACS patients (50.2% women) aged ≥80 years old between January 2013 and May 2020 were recruited in this study. All patients were divided into four groups according to gender and treatment: male PCI (n = 321) and conservative management groups (n = 513), and female PCI (n = 283) and conservative management groups (n = 559). Clinical and coronary lesion characteristics were compared among four groups, also the clinical outcomes. MACCE and their predictive factors were assessed using Kaplan–Meier curve and Cox regression analysis.

Results: PCI procedures were conducted in 604 patients, and 1,072 were conservative management. Men were most likely to present with prior myocardial infarction (MI), peripheral artery disease, and chronic total occlusion (CTO); women had a higher prevalence of hypertension and dyslipidemia. The proportion of men receiving PCI procedures was significantly higher than that of women (38.5 vs. 33.6%, p = 0.038). Compared to conservative management, successful PCI significantly improved composite MACCE in both men (33.9 vs. 18.4%, p < 0.001) and women (27.9 vs. 20.8%, p = 0.026). There were no differences between sex in the improvement of clinical outcomes after PCI. In addition, age, ST-segment elevation myocardial infarction (STEMI), log N-terminal pro-brain natriuretic peptide (NT-proBNP), P2Y12 receptor antagonist, and β-blocker were independently associated with the incidence of MACCE after PCI tested by the Cox regression model, but not gender (male: hazard ratio (HR) 1.275, 95% confidence interval (CI) 0.853–1.905, p = 0.236).
Conclusion: In this very elderly ACS cohort, men presented with more complex clinical conditions, and women were less likely to receive PCI treatment. Both women and men had similar benefits from the PCI procedure in the decrease of MACCE.

KEYWORDS
very elderly patients, acute coronary syndromes, percutaneous coronary intervention, sex differences, major adverse cardiovascular and cerebrovascular events

Background

Acute coronary syndrome (ACS) has been the leading cause of death in the past few decades. Fortunately, the application of percutaneous coronary intervention (PCI) had significantly improved the clinical outcomes in these patients (1, 2). With the progress of aging worldwide, very elderly patients with ACS have formed a large population, who need timely and effective treatment. However, this population had received significantly less invasive angiography and PCI treatment in clinical practice (3, 4), and was often excluded from large multicenter clinical studies (5, 6), because of possible higher risk of complications and mortality (7, 8), as well as the cardiologists may have fewer experiences and knowledge of PCI treatment in very elderly ACS patients.

Previous studies have also revealed that there are sex-related differences in clinical characteristics, outcomes, and quality of life (QoL) in patients with ACS after PCI. For example, women are more likely to have atypical symptoms and nonobstructive coronary disease on angiography (9–11), and less likely to receive guideline-based therapies or cardiac rehabilitation (9, 12). Women often have higher rates of periprocedural complications and mortality with PCI (12–14). Independent of the ACS presentation or comorbidities, the female sex was a predictor of poorer QoL following PCI for ACS (15), including significantly higher pain, anxiety, and depression. However, there are few specific descriptions of sex-related influence on the very elderly ACS patients after PCI. Awareness of these differences in the very elderly population may lead to improved sex-based diagnosis and treatment strategies, as well as the assessment of prognosis.

The aims of the present study were to investigate the sex-related differences in clinical characteristics, effectiveness, and safety of PCI treatment, and predictive factors of major adverse cardiovascular and cerebrovascular events (MACCE) after PCI in very elderly ACS patients.

Materials and methods

Study population and protocol

We retrospectively enrolled ACS patients aged 80 years or older (n = 1,676) between January 2013 and May 2020, who entered the Cardiovascular Center of Beijing Friendship Hospital Database (CBD) Bank. The study flow chart and protocol were described in Figure 1: (1) Consecutive ACS patients aged ≥80 years old (n = 1,676) were enrolled. (2) All the patients were classified by gender: female group (n = 842), and male group (n = 834). (3) Within the male group, patients were categorized into the male PCI group (M-PCI group, n = 321) and the male conservative management group (M-con group, n = 513). (4) Within the female group, patients were divided into the female PCI group (F-PCI group, n = 283) and the female conservative management group (F-con group, n = 559). (5) All the patients undergoing PCI were divided into groups with (n = 118) and without MACCE (n = 486), according to whether MACCE occurred or not during the follow-up period. Clinical characteristics on admission and incidences of MACCE during follow-up were compared in different sex groups and treatment groups. Meanwhile, predictive factors for MACCE after PCI were detected and assessed in this very elderly cohort.

ACS, including ST-elevation myocardial infarction (STEMI), non-ST-elevation MI (NSTEMI), and unstable angina pectoris (UAP), were diagnosed by symptoms, electrocardiogram (ECG) changes, and cardiac biomarkers. The treatment options (conservative management or PCI) were decided by two
Patients’ enrollment flow. ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; MACCE, major adverse cardiovascular and cerebrovascular events; con, conservative management.

Clinical outcomes and covariates

The patients’ demographic information, initial clinical presentation at admission, and past medical history (hypertension, diabetes, dyslipidemia, prior MI/stroke, and smoking) were retrospectively collected from the clinical information database. Laboratory examination results included high sensitivity C-reactive protein (hs-CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase-MB (CK-MB), hemoglobin A1c (HbA1C), lipid spectrum, and creatinine that were measured during hospitalization. M-mode and two-dimensional echocardiography (ECHO) were performed (Philips IE33 or EPIQ 7C) for routine parameters, such as left ventricular end-diastolic diameter (LVEDD) and ejection fraction (LVEF). The characteristics of stent implantation and coronary artery were detected by angiographic and PCI procedures, presented in the medical records.

Chronic total occlusion (CTO) referred to 100% coronary artery occlusion with thrombolysis in myocardial infarction (TIMI) grade 0 flow and angiographic evidence of occlusion duration > 3 months (17). Successful PCI was defined as final residual diameter stenosis <20% by visual estimation and the presence of normal epicardial coronary flow (TIMI-3 flow) (18). Major hemorrhage was defined by TIMI criteria as hemoglobin decrease ≥ 5 g/dl or any intracranial bleeding (19). Medication after discharge was determined from the medical records or regular telephone follow-up. The primary endpoint was composite MACCE, which was the combination of non-fatal MI, stroke, heart failure requiring hospitalization (HFRH), and cardiovascular (CV) death. The secondary endpoints referred to all-cause death and each of the adverse events mentioned above. All MACCEs were confirmed by two separate cardiologists simultaneously. Regular follow-up was conducted by clinic visits or phone interviews every 1–3 months until May 2021.
### Statistical analysis

Continuous variables were expressed as median with interquartile range and were compared by the Mann–Whitney U test. Categorical data were expressed as frequencies or percentages and were compared by Chi-square or Fisher’s exact statistics. The events of primary and secondary endpoint were compared among F-PCI, F-con, M-PCI, and M-con groups by

| TABLE 1: Baseline clinical characteristics in very elderly ACS patients. |
|---------------------------------------------------------------|
| **Variables** | Male ACS ($n = 834$) | Female ACS ($n = 842$) | **p value** | Male-PCI ($n = 321$) | Female-PCI ($n = 283$) | **p value** |
|----------------|----------------------|----------------------|-------------|----------------------|----------------------|-------------|
| Age, years     | 82 (81.85)           | 82 (81.84)           | 0.994       | 82 (81.84)           | 82 (81.84)           | 0.887       |
| BMI, kg/m²     | 24.33 (22.09,26.68)  | 24.44 (22.22,26.94)  | 0.808       | 24.22 (22.31,26.46)  | 24.43 (22.27,26.77)  | 0.763       |
| **Initial presentation** | | | | | | |
| Heart rate, beats/min | 70 (62.80) | 70 (64.80) | 0.227 | 69 (61.79) | 70 (64.80) | 0.034 |
| Systolic BP, mmHg | 133 (120,147) | 133 (121,148) | 0.279 | 132 (121,147) | 135 (120,150) | 0.151 |
| Diastolic BP, mmHg | 71 (64.80) | 70 (63.80) | 0.024 | 71 (64.80) | 70 (63.80) | 0.217 |
| **Past medical history** | | | | | | |
| Hypertension, n (%) | 603 (72.3) | 700 (83.1) | <0.001 | 229 (71.3) | 227 (80.2) | 0.011 |
| Diabetes mellitus, n (%) | 273 (32.7) | 303 (36.0) | 0.161 | 103 (32.1) | 96 (41.4) | 0.931 |
| Dyslipidemia, n (%) | 302 (36.2) | 356 (42.3) | 0.011 | 111 (42.0) | 105 (41.4) | 0.931 |
| Prior MI, n (%) | 129 (15.5) | 80 (9.5) | <0.001 | 49 (15.3) | 24 (8.5) | 0.011 |
| Prior stroke, n (%) | 226 (27.1) | 220 (26.1) | 0.653 | 73 (22.7) | 67 (23.7) | 0.786 |
| Smoking, n (%) | 171 (20.5) | 73 (8.7) | <0.001 | 75 (23.4) | 31 (11.0) | <0.001 |
| Prior PAD, n (%) | 97 (11.6) | 67 (8.0) | 0.011 | 37 (11.5) | 23 (8.1) | 0.163 |
| **Clinical diagnosis** | | | | | | |
| UAP, n (%) | 481 (57.7) | 513 (60.9) | 0.175 | 133 (41.4) | 130 (45.9) | 0.265 |
| NSTEMI, n (%) | 193 (23.3) | 184 (21.9) | 0.490 | 79 (24.6) | 65 (23.0) | 0.636 |
| STEMI, n (%) | 159 (19.1) | 145 (17.2) | 0.327 | 109 (34.0) | 88 (31.1) | 0.454 |
| Length of stay, days | 7 (6.10) | 7 (6.10) | 0.635 | 8 (6.11) | 7 (6.10) | 0.088 |
| **Laboratory finding** | | | | | | |
| HS-CRP, mg/L | 3.28 (1.06,14.45) | 2.78 (0.94,11.77) | 0.042 | 3.38 (1.37,15.15) | 3.44 (1.14,11.28) | 0.366 |
| TC, mmol/L | 3.74 (3.17,4.38) | 4.33 (3.65,5.06) | <0.001 | 3.80 (3.52,4.38) | 4.45 (3.71,5.15) | <0.001 |
| LDL-C, mmol/L | 2.06 (1.65,2.54) | 2.41 (1.89,2.94) | <0.001 | 2.13 (1.73,2.54) | 2.50 (2.02,3.06) | <0.001 |
| TG, mmol/L | 1.03 (0.76,1.36) | 1.26 (0.92,1.72) | <0.001 | 1.08 (0.76,1.37) | 1.30 (0.94,1.84) | <0.001 |
| Hdl-C, mmol/L | 1.02 (0.89,1.19) | 1.17 (0.99,1.39) | <0.001 | 1.01 (0.87,1.16) | 1.14 (0.97,1.37) | <0.001 |
| Creatinine, umol/L | 95.0 (83.5,112.38) | 77.7 (65.9,95.5) | <0.001 | 91.8 (80.8,104.3) | 75.0 (64.0,90.4) | <0.001 |
| HbA1c, % | 6.1 (5.6,6.7) | 6.1 (5.7,7.0) | 0.033 | 6.1 (5.6,6.9) | 6.2 (5.7,7.1) | 0.150 |
| First Glu, mmol/L | 5.45 (4.73,6.49) | 5.38 (4.84,6.74) | 0.184 | 5.58 (4.77,6.56) | 5.60 (4.86,7.19) | 0.202 |
| CK-MB, ng/ml | 1.9 (1.2,4.4) | 1.5 (1.0,3.2) | <0.001 | 2.75 (1.40,8.93) | 1.70 (1.0,4.50) | <0.001 |
| Log NT-proBNP | 3.03 (2.52,3.60) | 3.0 (2.50,3.56) | 0.670 | 2.96 (2.49,3.44) | 2.98 (2.56,3.46) | 0.360 |
| LVEF ≥ 50%, n (%) | 630 (78.9) | 707 (87.5) | 0.001 | 247 (78.4) | 241 (87.0) | 0.006 |
| LVEDD, mm | 5.23 (4.90,5.65) | 4.99 (4.62,5.23) | <0.001 | 5.20 (4.90,5.60) | 4.90 (4.64,5.20) | <0.001 |

*P2Y12 receptor antagonist within 12 months after PCI. p, level of statistical significance.

BMI, body mass index; BP, blood pressure; MI, myocardial infarction; PAD, peripheral artery disease; UAP, unstable angina pectoris; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; hs-CRP, high sensitivity C-reactive protein; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; ALT, alanine aminotransferase; HbA1c, Hemoglobin A1c; Glu, glucose; CK-MB, creatine kinase-MB; NT-proBNP, N-terminal pro-brain natriuretic peptide; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.
Results

Sex differences in clinical and coronary artery characteristics

The median follow-up duration of the study was 48 months (interquartile range, 24–60 m). The clinical characteristics of this very elderly ACS cohort were summarized in Table 1. Of the 1,676 patients, there was a similar proportion of men and women. Age, BMI, and types of clinical diagnosis were also matched between the sexes. But the rate of male ACS patients receiving PCI procedures was significantly higher than that of female patients ($p = 0.038$) (Figure 2). In past medical history, male patients had a higher prevalence of prior MI ($p < 0.001$) and peripheral artery disease (PAD, $p = 0.011$), and female patients had a greater history of hypertension ($p < 0.001$) and dyslipidemia ($p = 0.011$). As for the laboratory finding, male patients showed significantly higher levels of hs-CRP, creatinine,
CK-MB, and LVEDD, compared to female patients. Meanwhile, female patients were detected to have noticeably higher levels of low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), HbA1C, and proportion of LVEF ≥ 50%. During the follow-up period, the percentage of men taking aspirin was significantly higher than that of women ($p = 0.005$).

As described in Table 2, the rate of left main (LM) lesions and three-vessel lesions were similar between male and female ACS patients who underwent PCI procedures. However, the rate of CTO in males was higher than that in females ($p = 0.007$). There were no significant differences in post-PCI TIMI 3 flow, procedural success rate, and stent number between the males and females.

### Clinical factors related to PCI decision making

All the baseline variables entered the logistic regression analysis to detect factors related to PCI decision-making.

| Variables                  | Male-PCI         | Female-PCI        | $p$ value |
|----------------------------|------------------|-------------------|-----------|
| Primary PCI, n (%)         | 61 (19.0)        | 63 (22.3)         | 0.323     |
| LM disease, n (%)          | 71 (22.2)        | 50 (17.7)         | 0.167     |
| Three-vessel lesion, n (%) | 288 (90.0)       | 241 (85.2)        | 0.071     |
| CTO rate, n (%)            | 43 (13.4)        | 19 (6.7)          | 0.007     |
| Post-PCI TIMI 3 flow, n (%)| 298 (95.8)       | 273 (96.8)        | 0.525     |
| Procedural success rate, n (%) | 303 (97.1)      | 273 (96.8)        | 0.828     |
| Stent number ≥ 2, n (%)    | 146 (46.8)       | 114 (40.4)        | 0.118     |
| IABP use, n (%)            | 13 (4.0)         | 12 (4.2)          | 0.907     |
| Major bleeding, n (%)      | 10 (3.1)         | 16 (5.7)          | 0.125     |

$p$, level of statistical significance.

PCI, percutaneous coronary intervention; LM, left main; CTO, chronic total occlusion; TIMI, thrombolysis in myocardial infarction; IABP, intra-aortic balloon pump.

### Predictors of MACCE in the very elderly cohort undergoing PCI procedure

Univariate Cox regression analysis identified 10 factors, which might be associated with the occurrence of composite MACCE in very elderly patients after PCI, including age, sex, BMI, STEMI, log NT-proBNP, creatinine, and the use of aspirin, P2Y12 receptor antagonist, statin, and β-blocker. Further multivariate analysis confirmed that five factors independently associated with MACCE, involving age, STEMI, log NT-proBNP, and the use of P2Y12 receptor antagonist, and β-blocker. Remarkably, gender was not a related factor to the risk of MACCE in this special population (male: HR $1.275$, $p = 0.236$) (Table 4 and Figure 3), which meant that the predictors of MACCE after PCI were similar in both sexes in the present cohort.

### Clinical outcomes in the male and female ACS patients

The primary and secondary endpoints were displayed in Table 5. Compared to conservative management groups, PCI treatment significantly improved primary endpoints (composite MACCE) in both the male ($p < 0.001$) and female ($p = 0.026$) separately in the very elderly ACS population. Furthermore, PCI procedure significantly attenuated the risk of non-fatal MI ($p$
| Variables                      | Univariate regression | Multivariate regression |
|-------------------------------|-----------------------|-------------------------|
|                               | HR 95% CI             | p value                 | HR 95% CI             | p value                 |
| Age                           | 1.099 1.032–1.171     | 0.003                   | 1.071 1.004–1.143     | 0.036                   |
| Male                          | 1.205 0.840–1.729     | 0.311                   | 1.275 0.853–1.905     | 0.236                   |
| BMI                           | 0.944 0.893–0.997     | 0.040                   | 0.976 0.920–1.035     | 0.417                   |
| STEMI                         | 1.756 1.221–2.527     | 0.002                   | 1.522 1.030–2.251     | 0.035                   |
| log NT-proBNP                | 1.936 1.430–2.620     | <0.001                  | 1.708 1.215–2.400     | 0.002                   |
| Creatinine, umol/L           | 1.005 1.000–1.009     | 0.056                   | 1.001 0.995–1.006     | 0.846                   |
| Aspirin                      | 0.527 0.325–0.852     | 0.009                   | 1.044 0.579–1.884     | 0.885                   |
| P2Y12 receptor antagonist    | 0.358 0.219–0.587     | <0.001                  | 0.319 0.181–0.561     | <0.001                  |
| Statin                       | 0.486 0.314–0.751     | 0.001                   | 0.601 0.356–1.015     | 0.057                   |
| β-blocker                    | 0.597 0.416–0.858     | 0.005                   | 0.639 0.429–0.950     | 0.027                   |

*p* level of statistical significance.

MACCE, major adverse cardiovascular and cerebrovascular events; PCI, percutaneous coronary intervention; BMI, body mass index; STEMI, ST-elevation myocardial infarction; NT-proBNP, N-terminal pro-brain natriuretic peptide.

**FIGURE 3**
Factors independently associated with composite MACCE in PCI group in multivariable Cox regression analysis. BMI, body mass index; STEMI, ST-elevation myocardial infarction; NT-proBNP, N-terminal pro-brain natriuretic peptide; PCI, percutaneous coronary intervention; MACCE, major adverse cardiovascular and cerebrovascular events.

\[ p = 0.032 \], HFRH \( (p < 0.001) \), CV death \( (p < 0.001) \), and all-cause death \( (p < 0.001) \) in male ACS patients. In addition, female patients benefited significantly from PCI treatment in the decrease of HFRH \( (p < 0.001) \), CV death \( (p = 0.005) \), and all-cause death \( (p = 0.006) \) when compared to conservative management only. Finally, there were no remarkable differences in the clinical outcomes treated with PCI between sexes during the follow-up period. Kaplan–Meier curves (Figure 4) illustrated...
and compared the incidences of primary and secondary endpoints of the four groups in detail.

**Discussion**

The present study focused on the sex-related differences in PCI treatment in clinical outcomes in very elderly ACS patients. The investigation of differences involved clinical and coronary features, as well as long-term outcomes after PCI and their predictors between the male and female very elderly ACS patients. The results revealed that men tended to have more complex clinical conditions, the male gender was one of the independent factors driving the option of the PCI strategy, and women were less likely to receive PCI procedures in the very elderly cohort. Coronary artery lesions were relatively severe in both sexes, and the ratio of CTO lesions in men was significantly higher than that in women. Furthermore, the PCI procedure significantly decreased the incidence of MACCE in both sexes during follow-up, and there was no gender difference in the benefits of PCI treatment between the sexes. Finally, STEMI, elderly age, and increase in Log NT-proBNP value were independently associated with the risk of MACCE after PCI in the very elderly cohort.

Several studies had shown that there might be some differences between gender of ACS patients in clinical characteristics, efficacy, and safety of PCI procedure, and long-term prognosis (12–14). Very elderly patients are a special group with body hypofunction, more comorbidities, more PCI complications, and high mortality (20). Therefore, very elderly ACS patients have less PCI treatment experience and more concerns. In particular, the sex-related differences in this cohort after PCI is less known. With the aging worldwide, the population of very elderly ACS patients is growing rapidly (20), and the demand for PCI treatment is also increasing. The exploration of efficacy and gender differences of PCI procedure in the very elderly ACS population will contribute to gender-based therapeutic decisions and improve clinical outcomes in this population.

It has been found that female was less likely than male to undergo revascularization in the treatment of ACS in previous studies (9, 21, 22). This study detected the same trend in the very elderly ACS cohort, indicating that the proportion of very elderly female patients receiving PCI was significantly lower than that of the male. Logistic regression analysis verified that male gender was one of the independent factors, driving the option of PCI strategy. Meanwhile, the male tended to be admitted to hospitals with more complex clinical conditions, such as a higher proportion of prior MI, PAD, and smoking, higher levels of hs-CRP, creatinine, and CK-MB, and a lower proportion of LVEF ≥50%. In addition, it was recognized that age, STEMI, level of creatinine, and log NT-proBNP were also driving factors affecting PCI therapeutic decisions.

According to some clinical trials and registries, women had less multivessel disease or left-main disease than men (10, 11), but our study did not find significant differences in three-vessel stenosis and LM disease between genders. The reason may be that the subjects of the present study were a very elderly population, and the proportions of three-vessel stenosis and LM disease were higher in very elderly ACS patients in previous studies (20, 23). However, the CTO ratio in male patients was significantly higher than that in female patients (p = 0.007). Despite this, procedural success rates of PCI were relatively high in this very elderly cohort, which was similar to the previous study (24). Importantly, this study found no differences in success rates (p = 0.828) and stent numbers (p = 0.118) between genders, which demonstrated the feasibility and effectiveness of the PCI procedure in both sexes, especially in females.

PCI procedure had been proven to improve clinical outcomes of elderly patients with ACS (20, 25). The present study demonstrated that PCI treatment synchronously reduced the risk of MACCE in both genders (including composite

---

TABLE 5 The comparison of MACCE in PCI and conservative management group by different sexes.

| Variables                  | Male-con (n = 513) | Male-PCI (n = 321) | p value | Female-con (n = 559) | Female-PCI (n = 283) | p value | p value*
|----------------------------|-------------------|-------------------|---------|---------------------|--------------------|---------|---------
| Composite MACCE, n (%)    | 174 (33.9)        | 59 (18.4)         | <0.001  | 156 (27.9)          | 59 (20.8)          | 0.026   | 0.445   
| Non-fatal MI, n (%)       | 42 (8.2)          | 14 (4.4)          | 0.032   | 57 (10.2)           | 21 (7.4)           | 0.189   | 0.108   
| Stroke, n (%)             | 20 (3.9)          | 8 (2.5)           | 0.273   | 6 (1.1)             | 8 (2.8)            | 0.084*  | 0.798   
| HFRH, n (%)               | 65 (12.7)         | 17 (5.3)          | <0.001  | 90 (16.1)           | 23 (8.1)           | <0.001  | 0.163   
| CV death, n (%)           | 94 (18.3)         | 30 (9.3)          | <0.001  | 96 (17.2)           | 28 (9.9)           | 0.005   | 0.820   
| All-cause death, n (%)    | 148 (28.8)        | 54 (16.8)         | <0.001  | 128 (22.9)          | 42 (14.8)          | 0.006   | 0.506   
| Major bleeding, n (%)     | 16 (3.1)          | 10 (3.1)          | 0.998   | 4 (0.7)             | 16 (5.7)           | <0.001  | 0.125   

*Fisher’s exact test; p, level of statistical significance.
Male-PCI vs. Female-PCI
MACCE, major adverse cardiovascular and cerebrovascular events; con, conservative management; PCI, percutaneous coronary intervention; MI, myocardial infarction; HFRH, heart failure requiring hospitalization; CV, cardiovascular.
MACCE, CV death, and HFRH) compared to conservative management. Although the PCI procedure significantly increased the risk of TIMI-major bleeding ($p < 0.001$) in females, it did not offset the benefit of all-cause mortality in women. Meanwhile, this study revealed that the benefit of PCI in improving clinical outcomes was not different between genders. The above results suggested that both male and female very elderly ACS patients should consider more aggressive PCI strategies, especially female patients. Further investigations showed that gender was not the independent factor associated with MACCE after PCI, but age, STEMI, and worse cardiac function independently predicted the risk of MACCE during the follow-up. Also, adherence to P2Y12 receptor antagonist and β-blocker was important, which contributed to decrease the risk of MACCE in the very elderly PCI cohort. Statin was not shown to be associated with the risk of MACCE after PCI during follow-up (HR 0.601, $p = 0.057$) because of the high rates of statin use in this population.

Limitations

Single-center data and retrospective design are the main limitations of the present study. Treatment strategy reflected the convention and tendency of the single center,
which may have an important impact on clinical prognosis. Therefore, the conclusion may have been biased because the objectivity of the results may have been compromised. The retrospective design may miss some characteristics of the patients in the study, such as the evaluation of physical performance and acute kidney injury, which are common in the very elderly cohort. These factors might have some influences on the clinical outcomes of PCI treatment. In addition, the small sample size is also a constraint, resulting in an 8-year time span for enrolled patients, and the inability to include more stratified variables.

Conclusion

Very elderly male ACS patients tended to have more complex clinical conditions and were more likely to receive PCI procedures. PCI treatment had a relatively high procedural success rate and simultaneously improved the long-term clinical outcomes in both male and female very elderly patients.

Besides the descriptions of clinical and coronary differences, the significance of this study is to confirm the benefits of PCI in the very elderly population, especially the benefits without gender differences. So active PCI strategies may be appropriate for very elderly patients, especially females, who should be considered for more aggressive coronary invasive interventions than previously.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

Ethics statement

The studies involving human participants were reviewed and approved by Institutional Review Board of Beijing Friendship Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

J-lW performed the study, statistical analysis, and wrote the manuscript. X-qH contributed to the acquisition of data and analysis and interpretation of data. H-wl and HC provided support and designed the study. C-γG participated in the study data collection. S-mZ contributed to the conception or design and critically revised the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by National Key R&D Program of China (2021ZD0111004) and Beijing Key Clinical Subject Program.

Acknowledgments

We gratefully acknowledge the contributions of all staff who work at the CBD Bank.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. (2018) 39:119–77. doi: 10.1093/eurheartj/ehx393

2. Puymirat E, Simon T, Cayla G, Cottin Y, Elbaz M, Coste P, et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 Years in the FAST-MI program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. Circulation. (2017) 136:1908–19. doi: 10.1161/CIRCULATIONAHA.117.030798

3. Schoenenberger AW, Radovanovic D, Windecker S, Iglesias JE, Pedrazzini G, Stuck AE, et al. Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome. Eur Heart J. (2016) 37:1304–11. doi: 10.1093/eurheartj/ehv698

4. Malkin CJ, Prakash R, Chew DP. The impact of increased age on outcome from a strategy of early invasive management and revascularisation in patients with acute coronary syndromes: retrospective analysis study from the
related differences in the presentation, treatment and outcomes among patients persist in time to presentation, revascularization, and mortality in myocardial syndromes: insights from invasive and noninvasive coronary technologies.

Curr Atheroscler Rep. (2016) 18:73. doi: 10.1007/s11883-016-0629-7

6. Rich MW, Chyun DA, Skolnick AH, Alexander KP, Forman DE, Kitzman DW, et al. Knowledge gaps in cardiovascular care of the older adult population: a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society. Circulation. (2016) 133:2103–22. doi: 10.1161/CIRCULATIONAHA.110.003380

7. Avezzu A, Makdisse M, Spencer F, Gore JM, Fox KA, Montalescot G, et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. (2005) 149:67–73. doi: 10.1016/j.ahj.2004.06.003

8. Lattuca BK, Kerns M, Zeitzoni M, Cayla G, Guedenev P, Collet JP, et al. Elderly patients with ST-segment elevation myocardial infarction: a patient-centered approach. Drugs Aging. (2019) 36:531–9. doi: 10.1007/s40266-019-00663-y

9. Majidi M, Esami L, Ghorbani P, Foroughi M. Are women more susceptible to ischemic heart disease compared to men? A literature overview. J Geriatr Cardiol. (2021) 18:289–96. doi: 10.11909/j.issn.1671-5411.2021.04.004

10. Dey S, Flather MD, Devlin G, Brigger D, Gurfinkel EP, Steg PG, et al. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart. (2009) 95:20–6. doi: 10.1136/hrt.2007.138537

11. Chandrasekhar J, Mehran R. Sex-based differences in acute coronary syndromes: insights from invasive and noninvasive coronary technologies. JACC Cardiovasc Imaging. (2016) 9:451–64. doi: 10.1016/j.jcmg.2016.11.014

12. Kawamoto KR, Davis MB, Duvernoy CS. Acute coronary syndromes: differences in men and women. Curr Atheroscler Rep. (2016) 18:73. doi: 10.1007/s11883-016-0629-7

13. Stehli J, Martin C, Brennan A, Dinh DT, Leffkovits J, Zaman S. Sex differences persist in time to presentation, revascularization, and mortality in myocardial infarction treated with percutaneous coronary intervention. J Am Heart Assoc. (2018) 8:e012161. doi: 10.1161/JAHA.119.012161

14. Pancholy SB, Shantha GP, Patel T, Cheskin LJ. Sex differences in short-term and long-term all-cause mortality among patients with ST-segment elevation myocardial infarction treated by primary percutaneous intervention: a meta-analysis. JAMA Intern Med. (2014) 174:1822–30. doi: 10.1001/jamainternmed.2014.4762

15. Koh Y, Stehli J, Martin C, Brennan A, Dinh DT, Leffkovits J, et al. Does sex predict quality of life after acute coronary syndromes: an Australian, state-wide, multicentre prospective cohort study. BMJ Open. (2019) 9:e034034. doi: 10.1136/bmjopen-2019-034034

16. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedictu O, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. (2019) 40:87–165. doi: 10.1093/eurheartj/ ejy934

17. Galassi AR, Werner GS, Bouchiri M, Azzalini L, Mashayekhi K, Carlino M, et al. Percutaneous recalibration of chronic total occlusions: 2019 consensus document from the EuroCTO Club. EuroIntervention. (2019) 15:198–208. doi: 10.2424/eij-D-18-01826

18. Smith SC Jr, Dote JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation. (2001) 103:3019–41. doi: 10.1161/01.cir.103.24.3019

19. Chesebro JH, Knatterud G, Roberts R, Rorer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. (1987) 76:142–54. doi: 10.1161/01.cir.76.1.142

20. Shantagum VB, Harper R, Meredith J, Malaipan Y, Psalits P. An overview of PCI in the very elderly. J Geriatr Cardiol. (2015) 12:174–84. doi: 10.11909/j.issn.1671-5411.2015.02.012

21. Heer T, Schiele R, Schneider S, Gitt AK, Wienerberger H, Gottwick M, et al. Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry). Am J Cardiol. (2002) 89:511–7. doi: 10.1016/s0002-9149(01)02289-5

22. Heer T, Gitt AK, Juenger C, Schiele R, Wienerberger H, Towae F, et al. Gender differences in acute non-ST-segment elevation myocardial infarction. Am J Cardiol. (2006) 98:160–6. doi: 10.1016/j.amjcard.2006.01.072

23. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship J, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guidelines for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. (2012) 60:e44–e164. doi: 10.1016/j.jacc.2012.07.013

24. Numasawa Y, Inohara T, Ishii H, Yamaji K, Kohsaka S, Sawano M, et al. Comparison of outcomes after percutaneous coronary intervention in elderly patients, including 10 628 nonagenarians: insights from a japanese nationwide registry (J-PCI Registry). J Am Heart Assoc. (2019) 8:e011183. doi: 10.1161/JAHA.118.011017

25. Madhavan MV, Gersh BJ, Alexander KP, Granger CB, Stone GW. Coronary artery disease in patients >80 years of age. J Am Coll Cardiol. (2018) 71:2015–40. doi: 10.1016/j.jacc.2017.12.068

26. Damluji AA, Huang J, Bandeen-Roche K, Forman DE, Gerstenblith G, Moscucci M, et al. Frailty among older adults with acute myocardial infarction and outcomes from percutaneous coronary interventions. J Am Heart Assoc. (2019) 8:e013686. doi: 10.1161/JAHA.119.013686

27. Tonet E, Ariza-Solé A, Serenelli M, Formiga F, Sanchis I, Pavasini R, et al. The impact of sex and physical performance on long-term mortality in older patients with myocardial infarction. BMC Med. (2022) 20:15. doi: 10.1186/s12951-022-00211-4

28. Cosentino N, Resta ML, Somaschini A, Campodinico I, Lucchi C, Moltrasio M, et al. Acute kidney injury and in-hospital mortality in patients with ST-elevation myocardial infarction of different age groups. Int J Cardiol. (2021) 344:8–12. doi: 10.1016/j.ijcard.2021.09.023